Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer AgentsBinbin Cheng, Jianjun Chen, Guochao Liao et al.|Journal of Medicinal Chemistry|2020Cited by 85
Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer TreatmentBinbin Cheng, Wei Wang, Xiaoge Niu et al.|Journal of Medicinal Chemistry|2020Cited by 51
Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatmentBinbin Cheng, Jianjun Chen, Wei Wang et al.|Signal Transduction and Targeted Therapy|2023Cited by 29
Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual ImmunotherapyShuanghu Wang, Jian Xiao, Zhihua Kong et al.|Journal of Medicinal Chemistry|2024Cited by 21
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009–2024)Binbin Cheng, Jianjun Chen, Xian-Shi Ma et al.|European Journal of Medicinal Chemistry|2024Cited by 14